Compare TG Therapeutics Inc (TGTX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Union Co — how do they compare? TG Therapeutics Inc trades at $54.83 (market cap $8.16B), while Western Union Co trades at $6.13 (market cap $1.97B). The key difference: TG Therapeutics Inc is far larger — about 4.1× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Western Union Co for 96 Days on average.
| TGTX | WU | |
|---|---|---|
Market Cap | $8.16B | $1.97B |
Volume | 1,735,121 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $59.06 | $10.28 |
52-Week Low | $26.94 | $5.90 |
Typical Hold Time | 16 Days | 96 Days |
Enterprise Value | $8.37B | $1.88B |
Dividend Yield | — | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Western Union (WU) trades at $6.145, up 0.57% on the day, with a mixed technical signal leaning bearish in moving averages but bullish overall. The company shows strong profitability with a 43.97% ROE and a net income margin of 9.79%, though revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent earnings have missed expectations in Q1 and Q2 2026, while the pending Intermex acquisition and a $200M cost-cutting plan aim to bolster future performance amid competitive pressures.
The stock presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, supported by a consensus price target of $6.86 offering ~12% upside. However, risks include earnings volatility, regulatory hurdles for the Intermex deal, and declining revenue trends. Analyst sentiment is cautious with only 12% buy ratings, suggesting a hold stance may be prudent until earnings stabilize and strategic initiatives show clearer results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
